EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia: A Consensus Report by Hematologists and Cardiologists

Talha Munir, Eglė Čiburienė, Vasko Graklanov, Mariana Gospodinova, Ozren Jakšić, Luka Lipar, Imelda Marton, Anna Panovská, Lucia Petríková, Regina Pileckyte, Zoltan Pozsonyi, Miroslav Slanina und 2 weitere

Acta Haematologica · 2025

DOI: 10.1159/000547426 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Haematologica, 2025. Verfasst von Talha Munir und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK, tmunir@nhs.net. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Protein Kinase Inhibitors, Agammaglobulinaemia Tyrosine Kinase, Cardiovascular Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Cardiovascular (CV) adverse events (AEs), especially atrial fibrillation (AF) and hypertension, have been reported in patients receiving treatments for chronic lymphocytic leukemia (CLL), including Bruton’s tyrosine kinase inhibitors (BTKis). Although these AEs are managed effectively in most cases and AE management guidelines exist, practical management approaches are inconsistent across regions and practices. We aimed to address these inconsistencies by developing consensus recommendations. Summary: A European expert panel was assembled comprising eight hematologists and six cardiologists. Literature analysis, expert interviews, and the Delphi method were used to gain consensus on screening, monitoring, and treatment of AF and hypertension statements. Key Messages: Maintaining BTKi treatment is paramount to maximize time to next treatment; for patients at high risk of progression, this can be achieved by appropriately treating hypertension and AF and adjusting the BTKi dose. Patients should be risk-stratified as low, moderate, high, or very-high risk of cancer therapy-related CV toxicity and treated according to their disease status so that CLL treatment can be maintained. Patient education on symptom monitoring, home blood pressure monitoring, and electrocardiograms (baseline, every 3 months) are recommended to detect/monitor AF and hypertension. Close collaboration between hematologists and cardiologists is vital to achieve optimal patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellProtein Kinase InhibitorsAgammaglobulinaemia Tyrosine KinaseCardiovascular DiseasesAtrial FibrillationHumansHypertensionCardiologistsDisease Management

Stichwörter der Autor:innen

Bruton’s tyrosine kinase inhibitorsCardiovascular adverse eventsChronic lymphocytic leukemiaIbrutinib

Substanzen

Protein Kinase InhibitorsAgammaglobulinaemia Tyrosine KinaseBTK protein, human

Autor:innen und Institutionen

  • Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK, tmunir@nhs.net.
  • Cardiology and Angiology Center, Vilnius University Hospital, Vilnius, Lithuania.
  • Division of Hematology, Medical University of Plovdiv, Plovdiv, Bulgaria.
  • Cardiac Amyloidosis Reference Center and Expert Center for Hereditary Transthyretin Amyloidosis, University Hospital St Ivan Rilski, Sofia, Bulgaria.
  • Department of Hematology, University Hospital Dubrava, Zagreb, Croatia.
  • Department of Cardiology, UMC Ljubljana, Ljubljana, Slovenia.

Zitieren

APA

Munir, T., Čiburienė, E., Graklanov, V., Gospodinova, M., Jakšić, O., Lipar, L., Marton, I., Panovská, A., Petríková, L., Pileckyte, R., Pozsonyi, Z., Slanina, M., Škerget, M., & Bulj, N. (2025). Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia: A Consensus Report by Hematologists and Cardiologists. Acta Haematologica. https://doi.org/10.1159/000547426

Vancouver

Munir T, Čiburienė E, Graklanov V, Gospodinova M, Jakšić O, Lipar L, et al. Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia: A Consensus Report by Hematologists and Cardiologists. Acta Haematologica. 2025. doi:10.1159/000547426

BibTeX
@article{Munir2025,
  author = {Munir, Talha and Čiburienė, Eglė and Graklanov, Vasko and Gospodinova, Mariana and Jakšić, Ozren and Lipar, Luka and Marton, Imelda and Panovská, Anna and Petríková, Lucia and Pileckyte, Regina and Pozsonyi, Zoltan and Slanina, Miroslav and Škerget, Matevž and Bulj, Nikola},
  title = {Practical Management of Cardiovascular Adverse Events with BTKi Treatment in Patients with Chronic Lymphocytic Leukemia: A Consensus Report by Hematologists and Cardiologists},
  journal = {Acta Haematologica},
  year = {2025},
  doi = {10.1159/000547426}
}
Kostenlos starten →